GMP Cell Therapy Consumables Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-C

Cell Collection and Characterization/Sorting and Separation Segment to Lead GMP Cell Therapy Consumables Market during 2022-2028
According to our latest study on ""GMP Cell Therapy Consumables Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product, Cell Therapy, Process, and End Use,"" the market was valued at US$ 11,031.25 million in 2021 and is likely to reach US$ 59,985.89 million by 2028; it is estimated to grow at a CAGR of 27.5% from 2022 to 2028. The rise in research & development and drug discovery and the increase in strategic collaborations among companies are driving the market growth. However, stringent regulatory policies are hampering the growth of the GMP cell therapy consumables market.

For sample pages and special offers, please visit https://www.thinkingcapsrc.com/reports/1615/gmp-cell-therapy

Increase in Strategic Collaborations Drive GMP Cell Therapy Consumables Market Growth

For sample pages and special offers, please visit https://www.thinkingcapsrc.com/reports/1615/gmp-cell-therapy

The companies in the GMP cell therapy consumables market are making strategic collaborations for the development of new products and cell therapy treatments. A few strategic collaborations in the GMP cell therapy consumables market are mentioned below:

For sample pages and special offers, please visit https://www.thinkingcapsrc.com/reports/1615/gmp-cell-therapy

• In October 2022, Pluristyx, panCELLa, and Implant Therapeutics management announced the corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. The integrated technology and service offerings will greatly accelerate the development and delivery of revolutionary cell therapies to patients.
• In June 2022, CellPoint and AboundBio entered into definitive agreements with Galapagos, propelling Galapagos into next-generation cell therapy while significantly broadening its portfolio and capabilities. The aim of this agreement is to expand the current market for CAR-T therapies and have an important impact on patients needing additional and improved treatment options.
• In November 2021, Laurus Labs signed an investment agreement with Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company, to acquire a 26.62% stake (fully diluted basis), subject to the fulfillment of certain conditions.
The increase in strategic collaborations among market players for the development of cell therapy has propelled the use of GMP cell therapy consumables to achieve the desired products, which drives the growth of the GMP cell therapy consumables market.

For sample pages and special offers, please visit https://www.thinkingcapsrc.com/reports/1615/gmp-cell-therapy

Sartorius AG, Thermo Fisher Scientific Inc, Miltenyi Biotec BV & Co KG, Bio-Techne Corp, Corning Inc, FUJIFILM Irvine Scientific Inc, Lonza Group AG, BPS Bioscience Inc, Merck KGaA, and Global Life Sciences Solutions USA LLC are among the leading companies operating in the GMP cell therapy consumables market.

For sample pages and special offers, please visit https://www.thinkingcapsrc.com/reports/1615/gmp-cell-therapy

The GMP cell therapy consumables market, by product, is segmented into kits, reagents/molecular biology reagents, cell culture media and supplements, growth factors/cytokines and interleukins (including protein and nucleic acid purification buffers), and others. The kits segment held the largest market share in 2021. However, the growth factors/cytokines and interleukins segment is anticipated to register the highest CAGR during the forecast period. Based on cell therapy, the global GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. The T-cell therapy segment held the largest share of the market in 2021. However, the NK cell therapy segment is expected to register the highest CAGR during the forecast period. The GMP cell therapy consumables market, by end use, is segmented into clinical, commercial, and research. The clinical segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR in the market during the forecast period.

For sample pages and special offers, please visit https://www.thinkingcapsrc.com/reports/1615/gmp-cell-therapy

The GMP cell therapy consumables market, by process, is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/ quality assurance, and others. The cell collection and characterization/sorting and separation segment held the largest share of the market in 2021. However, the cryopreservation segment is anticipated to register the highest CAGR in the market during the forecast period. Based on geography, the GMP cell therapy consumables market is segmented into North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South & Central America. The market in North America is further segmented into the US, Canada, and Mexico. The market in Europe is subsegmented into France, Germany, the UK, the Netherlands, Italy, and the Rest of Europe. The APAC GMP cell therapy consumables market is subsegmented into China, India, Japan, Australia, Thailand, and the Rest of APAC. The market in the MEA is further segmented into Saudi Arabia, the UAE, South Africa, and the Rest of the MEA. The South & Central America GMP cell therapy consumables market is subsegmented into Brazil, Argentina, and the Rest of South & Central America.

For sample pages and special offers, please visit https://www.thinkingcapsrc.com/reports/1615/gmp-cell-therapy

Thinking Caps Market Reports
Bangalore, India
Sayantan Paul
CEO and Founder
+1 800 257 6445
connect@thinkingcapsrc.com

Thinking Caps is a research powerhouse dedicated towards making your business decisions easier, faster and cost effective.

Equipped with a multi-publisher dynamic repository of readily available syndicate industry reports, Thinking Caps helps you maximize RoI through incisive insights, credible data analysis, updated company information, and the opportunity to expand your horizon through additional bespoke research. We help you take tangible decisions positively impacting your business growth.

This release was published on openPR.